PURPOSE: Free doxorubicin (DXR) is not currently used to treat brain tumors because (i) the blood-brain barrier limits the drug deposition into the brain (ii) lethal toxic effects occur when combined with radiation therapy. Since encapsulation of DXR within liposomal carriers could overcome these drawbacks, the present study aimed at evaluating the radiosensitizing properties of non-pegylated (NPL-DXR) and pegylated (PL-DXR) liposomal doxorubicin on orthotopic high-grade glioma xenografts (U87). METHODS: DXR accumulation in brain tissues was assessed by a high-performance liquid chromatography method and antitumor efficacy was evaluated by mice survival determination. RESULTS: We showed that encapsulation of DXR ensured a preferential deposition of DXR in tumoral tissue in comparison with normal brain tissue: the best AUC tumor tissue/AUC normal tissue ratio depended greatly on the schedule. Overall, thanks to the optimization of the delivery schedule, we demonstrated a radiosensitizing effect for both liposomal DXR without toxicity of this combination on the U87 human malignant glioma orthotopic xenografts. CONCLUSION: This study shows that the use of nanocarriers, allowing targeting of intracerebral tumor, renders relevant the combination of anthracyclin with radiation therapy to treat brain tumors, opening a new field of therapeutic applications. However, our results point out that, for each new delivery system, the administration schedules need to be rigorously optimized.
PURPOSE: Free doxorubicin (DXR) is not currently used to treat brain tumors because (i) the blood-brain barrier limits the drug deposition into the brain (ii) lethal toxic effects occur when combined with radiation therapy. Since encapsulation of DXR within liposomal carriers could overcome these drawbacks, the present study aimed at evaluating the radiosensitizing properties of non-pegylated (NPL-DXR) and pegylated (PL-DXR) liposomal doxorubicin on orthotopic high-grade glioma xenografts (U87). METHODS: DXR accumulation in brain tissues was assessed by a high-performance liquid chromatography method and antitumor efficacy was evaluated by mice survival determination. RESULTS: We showed that encapsulation of DXR ensured a preferential deposition of DXR in tumoral tissue in comparison with normal brain tissue: the best AUC tumor tissue/AUC normal tissue ratio depended greatly on the schedule. Overall, thanks to the optimization of the delivery schedule, we demonstrated a radiosensitizing effect for both liposomal DXR without toxicity of this combination on the U87 human malignant glioma orthotopic xenografts. CONCLUSION: This study shows that the use of nanocarriers, allowing targeting of intracerebral tumor, renders relevant the combination of anthracyclin with radiation therapy to treat brain tumors, opening a new field of therapeutic applications. However, our results point out that, for each new delivery system, the administration schedules need to be rigorously optimized.
Authors: K J Harrington; G Rowlinson-Busza; K N Syrigos; R G Vile; P S Uster; A M Peters; J S Stewart Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatrin Bock; Christopher Dietmaier; Wolfgang Dietmaier; Jörg Dietrich; Christine Dudel; Franz Hübner; Tanya Jauch; Elisabeth Drechsel; Ingo Kleiter; Cäcile Wismeth; Anton Zellner; Alexander Brawanski; Andreas Steinbrecher; Jörg Marienhagen; Ulrich Bogdahn Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Susanna J E Veringa; Dennis Biesmans; Dannis G van Vuurden; Marc H A Jansen; Laurine E Wedekind; Ilona Horsman; Pieter Wesseling; William Peter Vandertop; David P Noske; GertJan J L Kaspers; Esther Hulleman Journal: PLoS One Date: 2013-04-29 Impact factor: 3.240
Authors: Martina da Ros; Anna Lisa Iorio; Maurizio Lucchesi; Alessia Stival; Maurizio de Martino; Iacopo Sardi Journal: Anticancer Agents Med Chem Date: 2015 Impact factor: 2.505
Authors: James F Hainfeld; Sharif M Ridwan; Yaroslav Stanishevskiy; Rahul Panchal; Daniel N Slatkin; Henry M Smilowitz Journal: Sci Rep Date: 2019-03-14 Impact factor: 4.379